Compare Altria Group Inc (MO) vs Novo Nordisk A/S (NVO) Price & Performance

Altria Group IncTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Altria Group Inc vs Novo Nordisk A/S — how do they compare? Altria Group Inc trades at $74.53 (market cap $124.67B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.

	MO	NVO
Market Cap	$124.67B	$220.53B
Sector	Consumer Staples	Health
52-Week High	$74.66	$71.70
52-Week Low	$54.72	$35.29
Enterprise Value	$145.75B	$239.49B
Dividend Yield	5.68%	3.63%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

Dividend Harvesting Portfolio tops $40K with 43.6% return, focusing on growing income and tech sector bets.Seeking Alpha · 1 day agoBullish SPYI ETF yields 12% but faces pressure as volatility drops and Treasury yields rise.24/7 Wall Street · 4 days agoNeutral View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 9 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 13 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About Altria Group Inc

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.